Equillium, Inc. — Investor Relations & Filings

Equillium is a clinical-stage biotechnology company that develops novel therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. The company leverages a deep understanding of immunobiology to create treatments designed to restore balance to the immune system. Its pipeline includes EQ504, a potent and selective Aryl Hydrocarbon Receptor (AhR) modulator with a non-immunosuppressive mechanism of action. Equillium also develops a multi-cytokine inhibitor platform that utilizes first-in-class structured-domain peptides to selectively inhibit multiple disease-driving cytokines while preserving other immune regulatory pathways.